EQS-Ad-hoc: BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)

BayWa AG / Key word(s): Half Year Report
BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)

27-Sep-2024 / 12:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The impairment tests that became necessary led to non-cash impairment losses of
€ 222.2 million, which were recognised as depreciation in the Half-Year Financial Statements 2024. At € 171.5 million, the largest share was attributable to BayWa r.e. AG, a 51% subsidiary of BayWa AG. These depreciations have no negative impact on the BayWa Group’s ongoing restructuring efforts and the implementation of the restructuring concept currently being developed.

The full Half-Year Financial Statements 2024 will be published today on the BayWa Group website.

Contact:

Josko Radeljic, BayWa AG, Head of Investor Relations,
tel. +49 (0)89/92 22-38 87, Fax +49 (0)89/92 12-38 87,
e-mail: josko.radeljic@baywa.de



 


End of Inside Information

27-Sep-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: BayWa AG
Arabellastraße 4
81925 Munich
Germany
Phone: +49 (0)89/ 9222-3691
Fax: +49 (0)89/ 9212-3680
E-mail: presse@baywa.de
Internet: www.baywa.com
ISIN: DE0005194062, DE0005194005,
WKN: 519406, 519400,
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1997511

 
End of Announcement EQS News Service

show this

zurück